Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Checkpoint blockade in cancer immunotherapy.

Alan J Korman1, Karl S Peggs, James P Allison

  • 1Medarex Inc., Milpitas, California, USA.

Advances in Immunology
|May 30, 2006
PubMed
Summary

Immune responses are regulated by checkpoints, like CTLA-4, that prevent autoimmunity but can hinder cancer immunotherapy. Blocking these checkpoints, particularly anti-CTLA-4, shows promise for generating antitumor activity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

The Lancet. Haematology·2026
Same author

A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCL.

Molecular therapy. Advances·2026
Same author

Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modeling.

Science immunology·2026
Same author

Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade.

bioRxiv : the preprint server for biology·2026
Same author

Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Cancer discovery·2025
Same author

Local T<sub>reg</sub> cell loss reprogrammes systemic antitumour immunity without breaking tolerance.

Nature reviews. Immunology·2025

Area of Science:

  • Immunology
  • Cancer Biology
  • Immunotherapy

Background:

  • Immune responses rely on balancing stimulatory and inhibitory signals.
  • Immunological checkpoints, such as the CD28/CTLA-4:B7.1/B7.2 pathway, regulate immune activity and prevent autoimmunity.
  • These checkpoints can impede effective anti-cancer immune responses.

Purpose of the Study:

  • To review the role of immunological checkpoints in immune regulation.
  • To discuss the therapeutic potential of checkpoint blockade in cancer immunotherapy.
  • To highlight anti-CTLA-4 therapy as a key example and explore other targets.

Main Methods:

  • Review of preclinical tumor models and clinical trial data for anti-CTLA-4 therapy.
  • Analysis of the mechanisms of immunological checkpoints.
  • Exploration of synergistic effects with other immunotherapies.

Main Results:

  • Anti-CTLA-4 blockade has demonstrated potential in preclinical and clinical settings for generating antitumor activity.
  • Checkpoint blockade can overcome peripheral tolerance mechanisms that protect against autoimmunity.
  • Combination therapies involving checkpoint blockade show promise.

Conclusions:

  • Targeting immunological checkpoints, exemplified by anti-CTLA-4, represents a promising strategy for cancer immunotherapy.
  • Overcoming inhibitory signals is crucial for enhancing anti-tumor immune responses.
  • Further research into checkpoint blockade and combination therapies is warranted.

Related Experiment Videos